{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:32:46Z","timestamp":1794004366649,"version":"4.8.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Inflammatory bowel disease (IBD) is a chronic immune-mediated condition of the gastrointestinal tract that requires chronic treatment and strict surveillance. Development of new monoclonal antibodies targeting one or a few single cytokines, including anti-tumor necrosis factor agents, anti-IL 12\/23 inhibitors, and anti-\u03b14\u03b27 integrin inhibitors, have dominated the pharmacological armamentarium in IBD in the last 20 years. Still, many patients experience incomplete or loss of response or develop serious adverse events and drug discontinuation. Janus kinase (JAK) is key to modulating the signal transduction pathway of several proinflammatory cytokines directly involved in gastrointestinal inflammation and, thus, probably IBD pathogenesis. Targeting the JAK-STAT pathway offers excellent potential for the treatment of IBD. The European Medical Agency has approved three JAK inhibitors for treating adults with moderate to severe Ulcerative Colitis when other treatments, including biological agents, have failed or no longer work or if the patient cannot take them. Although there are currently no approved JAK inhibitors for Crohn\u2019s disease, upadacitinib and filgotinib have shown increased remission rates in these patients. Other JAK inhibitors, including gut-selective molecules, are currently being studied IBD. This review will discuss the JAK-STAT pathway, its implication in the pathogenesis of IBD, and the most recent evidence from clinical trials regarding the use of JAK inhibitors and their safety in IBD patients.<\/jats:p>","DOI":"10.3389\/fmed.2023.1089099","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T04:57:30Z","timestamp":1677733050000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":102,"title":["JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases"],"prefix":"10.3389","volume":"10","author":[{"given":"Claudia","family":"Herrera-deGuise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Serra-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Lastiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Borruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1113\/JP275396","article-title":"The interplay between microbes and the immune response in inflammatory bowel disease.","volume":"596","author":"Goethel","year":"2018","journal-title":"J Physiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease.","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/apt.12507","article-title":"Review article: immunogenicity of anti-tnf biologics in ibd - the role of patient, product and prescriber factors.","volume":"38","author":"Moss","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"ii45","DOI":"10.1093\/rheumatology\/keaa896","article-title":"Jak1 inhibition and inflammatory bowel disease.","author":"Harris","year":"2021","journal-title":"Rheumatology (Oxford)."},{"key":"B5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/1381612825666190405141410","article-title":"Jak inhibition: the most promising agents in the IBD pipeline?","volume":"25","author":"Fernandez-Clotet","year":"2019","journal-title":"Curr Pharm Des."},{"key":"B7","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of jak-stat signalling in the immune system.","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat Rev Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S2468-1253(19)30414-5","article-title":"Small molecule oral targeted therapies in ulcerative colitis.","volume":"5","author":"Shivaji","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling.","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1177","article-title":"Crohn\u2019s disease and ulcerative colitis show unique cytokine profiles.","volume":"9","author":"Nemeth","year":"2017","journal-title":"Cureus."},{"key":"B11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"Jak-Stat pathway targeting for the treatment of inflammatory bowel disease.","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.molimm.2006.11.025","article-title":"Cytokine receptor signaling through the jak-stat-socs pathway in disease.","volume":"44","author":"O\u2019Sullivan","year":"2007","journal-title":"Mol Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (Cp-690,550).","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis.","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis.","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-World effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis.","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm Bowel Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","article-title":"Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised riveting trial.","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"Aga clinical practice guidelines on the management of moderate to severe ulcerative colitis.","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase iib randomised placebo-controlled trials.","volume":"66","author":"Panes","year":"2017","journal-title":"Gut."},{"key":"B21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.","volume":"13","author":"Gibson","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.cgh.2018.06.031","article-title":"Effect of accelerated infliximab induction on short- and long-term outcomes of acute severe ulcerative colitis: a retrospective multicenter study and meta-analysis.","volume":"17","author":"Nalagatla","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/ecco-jcc\/jjaa018","article-title":"Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience.","volume":"14","author":"Kotwani","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B25","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cgh.2018.11.022","article-title":"Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis.","volume":"17","author":"Berinstein","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.cgh.2018.11.022","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study.","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/ibd\/izab037","article-title":"Hit the road Jak! the role of new oral treatment in inflammatory bowel disease.","volume":"27","author":"Garrido","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (selection): a phase 2b\/3 double-blind, randomised, placebo-controlled trial.","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the fitzroy study): results from a phase 2, double-blind, randomised, placebo-controlled trial.","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet."},{"key":"B31","year":"2020","journal-title":"Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn\u2019s Disease (Diversity1)."},{"key":"B32","year":"2023","journal-title":"Filgotinib in Long-Term Extension Study of Adults with Crohn\u2019s Disease (Diversitylte)."},{"key":"B33","year":"2022","journal-title":"Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn\u2019s Disease (Divergence2)."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three Phase 3, multicentre, double-blind, randomised trials.","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"i87","DOI":"10.1093\/ecco-jcc\/jjab232.077","article-title":"Dop38 upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1.","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohn\u2019s Colitis."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac121","article-title":"Tofacitinib response in ulcerative colitis (tour): early response after initiation of tofacitinib therapy in a real-world setting.","author":"Long","year":"2022","journal-title":"Inflamm Bowel Dis."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.","author":"Burr","year":"2021","journal-title":"Gut"},{"key":"B38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease.","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology."},{"key":"B40","year":"2022","journal-title":"A Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants with Moderately to Severely Active Crohn\u2019s Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy."},{"key":"B41","year":"2023","journal-title":"A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants with Crohn\u2019s Disease Who Completed the Studies M14-431 or M14-433."},{"key":"B42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis.","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an oral janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, Phase 2 study.","volume":"12","author":"Sands","year":"2018","journal-title":"J Crohns Colitis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of gut-selective pan-janus kinase inhibitor Td-1473 for ulcerative colitis: a translational medicine programme.","volume":"14","author":"Sandborn","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjx003","article-title":"The future of janus kinase inhibitors in inflammatory bowel disease.","volume":"11","author":"De Vries","year":"2017","journal-title":"J Crohns Colitis."},{"key":"B46","year":"2022","journal-title":"Efficacy &amp; Safety of Td-1473 in Ulcerative Colitis."},{"key":"B47","year":"2022","journal-title":"Efficacy and Safety of Td-1473 in Crohn\u2019s Disease (Dione)."},{"key":"B48","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3892\/ijmm.2016.2692","article-title":"Targeted blockade of Jak\/Stat3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells.","volume":"38","author":"Gu","year":"2016","journal-title":"Int J Mol Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase ii study.","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology."},{"key":"B50","year":"2022","journal-title":"A Phase 3 Study to Investigate the Efficacy and Safety of Shr0302 with Moderately to Severely Active Ulcerative Colitis."},{"key":"B51","year":"2022","journal-title":"A Phase Ii Study in Patients with Moderate to Severe Active Crohn\u2019s Disease."},{"key":"B52","year":"2023","journal-title":"Study of Ost-122 in Patients with Moderate to Severe Ulcerative Colitis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.1074\/jbc.M114.619502","article-title":"Tyrosine Kinase 2-Mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain.","volume":"290","author":"Tokarski","year":"2015","journal-title":"J Biol Chem."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis.","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med."},{"key":"B55","year":"2023","journal-title":"An Investigational Study of Experimental Medication Bms-986165 in Participants with Moderate to Severe Crohn\u2019s Disease."},{"key":"B56","year":"2023","journal-title":"Safety and Efficacy of Deucravacitinib in Participants with Moderate to Severe Ulcerative Colitis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of Tyk2 and Jak1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-Methyl-1 H-Pyrazol-4-Yl)Amino)Pyrimidin-4-Yl)-3,8-Diazabicyclo[3.2.1]Octan-8-Yl)Methanone (Pf-06700841).","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus Kinase 3 (Jak3) Specific Inhibitor 1-((2s,5r)-5-((7h-Pyrrolo[2,3-D]Pyrimidin-4-Yl)Amino)-2-Methylpiperidin-1-Yl)Prop-2-En-1-One (Pf-06651600) allowing for the interrogation of Jak3 signaling in humans.","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J Med Chem."},{"key":"B59","year":"2022","journal-title":"Study to Evaluate the Efficacy and Safety of Oral Pf-06651600 and Pf-06700841 in Subjects with Moderate to Severe Crohn\u2019s Disease."},{"key":"B60","year":"2022","journal-title":"Study to Compare Oral Pf-06651600, Pf-06700841 and Placebo in Subjects with Moderate to Severe Ulcerative Colitis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib.","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving jak inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention.","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17379","article-title":"Systematic review with network meta-analysis: risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease.","author":"Din","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.651415","article-title":"Novel and emerging therapies for inflammatory bowel disease.","volume":"12","author":"Al-Bawardy","year":"2021","journal-title":"Front Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40261-021-01055-0","article-title":"Filgotinib in rheumatoid arthritis: a profile of its use.","volume":"41","author":"Kim","year":"2021","journal-title":"Clin Drug Investig."},{"key":"B66","doi-asserted-by":"publisher","first-page":"S755","DOI":"10.1093\/ecco-jcc\/jjaa017","article-title":"Jak inhibitors safety in ulcerative colitis: practical implications.","author":"Agrawal","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100096","article-title":"User\u2019s guide to jak inhibitors in inflammatory bowel disease.","volume":"3","author":"Spiewak","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov."},{"key":"B68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.gastrohep.2020.04.012","article-title":"Pharmacology and safety of tofacitinib in ulcerative colitis.","volume":"44","author":"Lopez-Sanroman","year":"2021","journal-title":"Gastroenterol Hepatol."},{"key":"B69","first-page":"181","article-title":"An overview of lipid abnormalities in patients with inflammatory bowel disease.","volume":"24","author":"Agouridis","year":"2011","journal-title":"Ann Gastroenterol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002145","article-title":"Real-World evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness and safety.","author":"Chaparro","year":"2022","journal-title":"Am J Gastroenterol."},{"key":"B72","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis.","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology."},{"key":"B73","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral janus kinase inhibitor.","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum."},{"key":"B74","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis.","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B75","article-title":"Relationship between changes in lipid levels and improvement in disease activity outcomes in patients with rheumatoid arthritis receiving upadacitinib treatment: pooled analysis of data from two Phase 3 studies [Abstract].","volume":"72","author":"Charles-Schoeman","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.2494","article-title":"Fri0344 the long-term effect of treating psoriatic arthritis with the Janus kinase 1-selective inhibitor filgotinib on lipid profiles: an analysis of the equator and equator2 trials.","volume":"79","author":"Husni","year":"2020","journal-title":"Ann Rheumat Dis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/ibd\/izaa227","article-title":"Lipid profiles in patients with ulcerative colitis receiving tofacitinib-implications for cardiovascular risk and patient management.","volume":"27","author":"Sands","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"B78","article-title":"The risk of venous thromboembolic events in patients with ra aged \u226550 years with \u22651 cardiovascular risk factor: results from a phase 3b\/4 randomized safety study of tofacitinib Vs Tnf inhibitors [Abstract].","author":"Charles-Schoeman","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of octave open, an open-label, long-term extension study with up to 7.0 years of treatment.","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"i514","DOI":"10.1093\/ecco-jcc\/jjab232.699","article-title":"P573 the safety profile of upadacitinib maintenance therapy in ulcerative colitis in the phase 3 U-achieve study is consistent with that in approved indications.","volume":"16","author":"Colombel","year":"2022","journal-title":"J Crohns Colitis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/17474124.2022.2138857","article-title":"Filgotinib for moderately to severely active ulcerative colitis.","volume":"16","author":"Mannucci","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European crohn\u2019s and colitis guidelines on sexuality, fertility, pregnancy, and lactation.","volume":"17","author":"Torres","year":"2023","journal-title":"J Crohns Colitis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/flgastro-2019-101371","article-title":"IBD in pregnancy: recent advances, practical management.","volume":"12","author":"Selinger","year":"2021","journal-title":"Frontline Gastroenterol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis.","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2021.1902617","article-title":"Filgotinib, a novel Jak1-Preferential inhibitor for the treatment of rheumatoid arthritis: an overview from clinical trials.","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1007\/s12325-022-02168-4","article-title":"Manta and manta-ray: rationale and design of trials evaluating effects of filgotinib on semen parameters in patients with inflammatory diseases.","volume":"39","author":"Hellstrom","year":"2022","journal-title":"Adv Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with jak inhibitors: a meta-analysis.","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B89","year":"2023","journal-title":"Janus Kinase Inhibitors (JAKi)."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical program.","author":"Sandborn","year":"2022","journal-title":"J Crohns Colitis."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211005708","article-title":"Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.","volume":"14","author":"Rubin","year":"2021","journal-title":"Therap Adv Gastroenterol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis.","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis.","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep."},{"key":"B95","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","article-title":"Tofacitinib for the treatment of pyoderma gangrenosum.","volume":"17","author":"Kochar","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac157","article-title":"Multicenter real-world experience of upadacitinib in the treatment of Crohn\u2019s disease.","author":"Chugh","year":"2022","journal-title":"J Crohns Colitis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/ibd\/izab097","article-title":"Real-World comparison of tofacitinib vs ustekinumab among bio-exposed patients with ulcerative colitis: a propensity score analysis.","volume":"27","author":"Dalal","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000859512.98331.3f","article-title":"One-Year comparative effectiveness of ustekinumab versus tofacitinib for ulcerative colitis after anti-tumor necrosis factor failure [Acg Abstract 42].","author":"Dalal","year":"2022","journal-title":"Am J Gastroenterol."},{"key":"B99","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","article-title":"Superior effectiveness of tofacitinib compared to vedolizumab in anti-tnf-experienced ulcerative colitis patients: a nationwide dutch registry study.","volume":"21","author":"Straatmijer","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/rheumatology\/keac285","article-title":"Comparison of drug retention of tnf inhibitors, other biologics and jak inhibitors in ra patients who discontinued jak inhibitor therapy.","volume":"62","author":"Amstad","year":"2022","journal-title":"Rheumatology (Oxford)."},{"key":"B101","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A Phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohn\u2019s disease.","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/apt.15072","article-title":"Long-Term safety and tolerability of oral tofacitinib in patients with Crohn\u2019s disease: results from a phase 2, open-label, 48-week extension study.","volume":"49","author":"Panes","year":"2019","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1089099\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T04:57:37Z","timestamp":1677733057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1089099\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":102,"alternative-id":["10.3389\/fmed.2023.1089099"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1089099","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"article-number":"1089099"}}